PE-22-28 has zero human safety or efficacy data. The mechanism is novel and compelling. The human translation is completely unknown. Do not use as a substitute for prescribed psychiatric medication without physician guidance.
COMPOUND PROFILE · PEPPERLEDGER
PE-22-28
Mazella J, Bhatt DL et al. · INSERM / University of Nice · Derived from spadin, the natural TREK-1 antagonist
Type
Synthetic heptapeptide — truncated analog of spadin (sortilin propeptide), the natural TREK-1 channel antagonist found in cerebrospinal fluid
Not FDA-approved · No human clinical trials · Research compound · Research chemical
Human evidence
None — all evidence is preclinical (rodent models)
Preclinical evidence
Moderate-strong — consistent antidepressant effects in multiple rodent paradigms; faster onset than fluoxetine in models; BDNF upregulation confirmed
EDUCATIONAL TOOL — NOT MEDICAL ADVICE
What is PE-22-28?
PE-22-28 targets a mechanism for depression that no approved antidepressant touches: TREK-1 potassium channels. TREK-1 (TWIK-related K+ channel 1) is a background potassium channel expressed in neurons throughout the brain's limbic system. When TREK-1 activity is too high, neurons are hyperpolarized and underactive — a state associated with depression. TREK-1 knockout mice are resistant to depression-like behavior and have elevated monoamine levels. PE-22-28 blocks TREK-1, restoring normal neuronal excitability.
The excitement comes from two things: the mechanism is completely novel — no approved drug works this way — and the onset appears faster than conventional antidepressants in preclinical models. SSRIs require 4–8 weeks to produce antidepressant effects. PE-22-28 produced antidepressant-like behavior in mouse models within 24–48 hours, with effects comparable to fluoxetine at 3 weeks achieved much faster.
PE-22-28 also upregulates BDNF in the hippocampus — the same downstream effect that accounts for antidepressants' long-term efficacy, but achieved faster and through a different upstream pathway. The honest picture: compelling preclinical story, zero human data. Users are extrapolating from rodent studies with uncharacterized human risk.
How it works
TREK-1 Channel Inhibition
TREK-1 is a two-pore domain potassium channel (K2P) contributing to background potassium conductance in neurons. When open, potassium flows out of the neuron, hyperpolarizing the membrane and reducing firing. In depression models, TREK-1 overactivity produces a hypoactive limbic system. PE-22-28 (derived from spadin, a natural TREK-1 antagonist in CSF) blocks TREK-1, shifting neuronal excitability toward a more active state and increasing serotonin, noradrenaline, and dopamine activity.
Monoamine Elevation — Same End Result, Different Upstream
TREK-1 inhibition increases the firing rate of serotonergic neurons in the raphe nucleus and noradrenergic neurons in the locus coeruleus — elevating serotonin and noradrenaline in limbic regions. This is the same end result that SSRIs and SNRIs produce, but through a completely different upstream mechanism. PE-22-28 doesn't block reuptake transporters — it increases the firing of the neurons that release monoamines in the first place.
BDNF Upregulation and Neuroplasticity
PE-22-28 increases BDNF expression in the hippocampus faster than conventional antidepressants in preclinical models. BDNF drives neurogenesis, synaptic plasticity, and dendritic spine formation — the structural brain changes underlying recovery from depression. The monoamine hypothesis has been challenged by the observation that SSRIs raise serotonin within hours but take weeks to treat depression — suggesting downstream neuroplasticity (BDNF, neurogenesis) is the actual therapeutic mechanism. PE-22-28's faster BDNF induction via TREK-1 inhibition may represent a more direct path to these changes.
What the research shows
PRECLINICAL ONLY — NO HUMAN TRIALS
STUDYPLOS Biology · 2010
Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: antidepressant effects
Mazella J et al.
Original characterization of spadin as a natural TREK-1 antagonist with antidepressant properties — the proof of concept that led to PE-22-28 development. Established the TREK-1 mechanism and the spadin-to-PE-22-28 development lineage.
Fighting depression with decoys: a new therapeutic approach targeting sortilin
Djillani A et al.
Characterized PE-22-28 as a more potent and stable truncated version of spadin. Antidepressant effects in forced swim and tail suspension paradigms in mice. Faster onset than fluoxetine in model comparisons. Established PE-22-28 as the lead TREK-1 inhibitor compound.
PE-22-28 has a small community primarily among people researching novel antidepressant mechanisms who have followed the TREK-1 literature. Reported effects: mood improvement described as cleaner and faster than oral antidepressants, anxiolytic effect alongside mood improvement, and no sexual side effects — the most commonly cited advantage over SSRIs. Response is highly variable, consistent with zero human dose-finding data. Often stacked with Selank (anxiolytic) or Semax (BDNF/cognition) in the mood peptide stack.
WHAT THE RESEARCH SHOWS
✓KNOWN
✓TREK-1 inhibition mechanism is well-characterized — PE-22-28 blocks the same receptor as natural spadin
✓Faster preclinical onset than fluoxetine — BDNF upregulation more rapid than SSRIs in models
✓No sexual side effects mechanism — TREK-1 inhibition doesn't act on serotonin transporters that cause SSRI sexual dysfunction
✓No human safety or efficacy data of any kind
?UNCERTAIN
?Human safety profile — completely unestablished
?Effective human dose — community range is extrapolated from rodent studies
?Whether the faster preclinical onset translates to humans (rodent models notoriously poor predictors of antidepressant efficacy)
?Long-term effects of TREK-1 inhibition — TREK-1 has roles beyond mood including pain processing, cardiac rhythm, and neuroprotection
?Interaction profile with prescribed psychiatric medications — serotonin syndrome risk with monoamine-elevating drugs
⚠ PSYCHIATRIC MEDICATION INTERACTION — HARD LIMIT
If you are on prescribed antidepressants (SSRIs, SNRIs, MAOIs, or any monoamine-affecting medication): do not combine PE-22-28 without physician guidance. TREK-1 inhibition increases monoamine activity — combining with drugs that also raise monoamines carries real risk of serotonin syndrome.
RECONSTITUTION CALCULATOR
EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN
AI COACH PREVIEW
I want to try PE-22-28 for mood support alongside my existing peptide stack. What dose and how does it compare to Selank?
PE-22-28 and Selank target completely different mechanisms — they're not competitors but they do address mood from different angles. Selank is GABAergic/GABA-A modulating with anxiolytic effects — it reduces anxiety without sedation. PE-22-28 is TREK-1 inhibiting with antidepressant-directed effects — it increases neuronal activity in limbic circuits and upregulates BDNF. They're genuinely complementary: Selank for the anxiety layer, PE-22-28 for the mood/energy layer. Before dose: the hard limit first — are you on any psychiatric medications? SSRIs, SNRIs, anything monoamine-affecting? If yes, this conversation ends there until you've talked to your prescriber. If no: community start point is 100–200 mcg SC daily in the morning. Effects in rodents appeared within 24–48 hours. If you're going to test this, track your mood daily with a consistent scale (0–10), track energy and motivation separately, note any side effects immediately. The variable response rate in the community is significant — some people respond strongly, some not at all. If you see no effect after 2 weeks at 200 mcg, there's no strong rationale to push higher given the absence of human dose-finding data.
CONTINUE IN THE APP
Open PepperLedger to track your PE-22-28 protocol →
Free to join. Log your daily mood and track the protocol carefully — given zero human data, systematic self-tracking is the only feedback loop available.
Free to join · No credit card · 23-day Pro trial included